Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma

Oncology
Takuji OkusakaM Yoshimori

Abstract

Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as > or = 50% reduction and/or > or = 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum alpha-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.

Citations

Feb 23, 2010·AJR. American Journal of Roentgenology·Kenichi TakayasuUNKNOWN Liver Cancer Study Group of Japan
Jun 25, 2013·Expert Opinion on Drug Delivery·Chetan YewaleAmbikanandan Misra
Aug 11, 2006·Nature Reviews. Cancer·Ruth Duncan
Sep 10, 2002·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·Kazuhito ShiratoKatsuaki Tanaka
Jan 22, 2003·International Journal of Urology : Official Journal of the Japanese Urological Association·Senji HoshiTakashi Yoshimoto
Mar 20, 2018·Molecular Pharmaceutics·Zheng-Rong Lu, Peter Qiao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.